Search results
Results from the WOW.Com Content Network
Current Oncology is a bi-monthly peer-reviewed medical journal covering oncology. It was established in 1994 and was originally published quarterly by Multimed Inc., a company founded in 1980 by Lorne Cooper. Its founders intended it to be a forum in which Canadian oncologists could publish their work. [1] The journal is now published bimonthly ...
JCO Oncology Practice [1] (known from 2005 to 2019 as the Journal of Oncology Practice) [2] is a monthly peer-reviewed medical journal covering the mechanics of oncology care. It was established in 2005 and is published by the American Society of Clinical Oncology. The editor-in-chief is John V. Cox (UT Southwestern Medical Center). [3]
In 2017, it contains review articles on 1,500 genes, 700 papers on leukemias, 220 on solid tumors, and 110 on hereditary disease with a cancer-prone condition and 110 "Deep Insights" on related subjects, 40,000 internal links and 730,000 external links. This represents 45,000 "web pages" (i.e. about 200,000 printed pages).
The Journal of Clinical Oncology is a peer-reviewed medical journal published 3 times a month by the Lippincott Williams & Wilkins. It covers research on all aspects of clinical oncology. The journal was established in 1983 and the editor-in-chief is Jonathan W. Friedberg (University of Rochester). JCO's Impact Factor is 45.3 as reported by ...
C. CA (journal) Cancer (journal) Cancer and Metastasis Reviews; Cancer Causes & Control; Cancer Cell (journal) Cancer Cell International; Cancer Chemotherapy and Pharmacology
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
Oncology Letters is a monthly peer-reviewed medical journal covering all aspects of oncology. It was established in 2010 and is published by Spandidos Publications. It was established in 2010 and is published by Spandidos Publications.
Innovative oncology, up 11%, seven oncology products we have in 2024. We think that's a very strong portfolio to help patients with oncology and hematology disease. Rare disease, up to about $4.5 ...